The Prostate and Urologic Cancer Research Group conducts and supports research on the prevention and early detection of prostate and bladder cancer. Clinical trials and the evaluation of new agents, surrogate biomarkers, and new technologies to identify premalignant lesions are developed and supported.

Read more About the Prostate and Urologic Cancer Research Group.

Funding Opportunity Announcements (FOA)

Number: PAR-19-183

Funding Opportunity Title: Biology of Bladder Cancer (R01 Clinical Trial Optional)
Activity Code: R01 Research Project Grant
Announcement Type: New

Companion Funding Opportunity: PAR-19-184, R21 Exploratory/Developmental Grant

Funding Opportunity Purpose
This Funding Opportunity Announcement (FOA) encourages applications investigating the biology and underlying mechanisms of bladder cancer. Bladder cancer is a significant health problem both in the United States and globally. Because of the high incidence and frequent tumor recurrence, bladder cancer exacts an outsized medical burden. While recent progress has been made in the molecular profiling of bladder cancers and identification of mutated genes, relatively little is known regarding the molecular mechanisms driving initiation, progression, and malignancy of bladder cancer. Furthermore, our understanding of biological processes of the normal bladder at the molecular, cell and organ levels is limited. Fundamental knowledge of how molecular and cellular functions of the bladder are altered in cancer will aid our understanding of bladder cancer biology and interventions. Applications that involve multidisciplinary teams and use clinical specimens or investigate both normal and cancer processes are encouraged.